Page 7 - அலோக் திவாரி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அலோக் திவாரி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அலோக் திவாரி Today - Breaking & Trending Today

SCR GM inspects projects in Guntakal division


SCR GM inspects projects in Guntakal division
Updated:
Updated:
Speed test conducted between Yathalur and Venkatagiri stations
Share Article
Speed test conducted between Yathalur and Venkatagiri stations
South Central Railway (SCR) General Manager Gajanan Mallya inspected the various ongoing projects in the Gudur-Renigunta and Tirupati-Katpadi sections of Guntakal division and expressed satisfaction at the pace and quality of the work.
As part of the annual inspection of the section undertaken on Tuesday along with Divisional Railway Manager (Guntakal division) Alok Tiwari, he inspected the safety aspects at the level crossing gate between Kondagunta and Vendodu stations.
Later, he reviewed the passenger amenities, inspected the Station Manager’s office, booking office, circulating area in Venkatagiri station and interacted with track maintenance staff. At the level crossing gate between Yathalur and Venkatagiri stations, the official conducted ....

Andhra Pradesh , Alok Tiwari , Gajanan Mallya , Central Railway , Divisional Railway , South Central Railway , General Manager Gajanan Mallya , Divisional Railway Manager , Station Manager , Net Zero Energy Stations , Scr Gm , Guntakal Division , ஆந்திரா பிரதேஷ் , அலோக் திவாரி , கஜனன் மல்லையா , மைய ரயில்வே , பிரிவு ரயில்வே , தெற்கு மைய ரயில்வே , ஜநரல் மேலாளர் கஜனன் மல்லையா , பிரிவு ரயில்வே மேலாளர் , நிலையம் மேலாளர் , நிகர பூஜ்யம் ஆற்றல் நிலையங்கள் , ஸ்க்ர் கம் , குண்டக்கல் பிரிவு ,

ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net Hospital Oncology Clinic


SHARE
ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net Hospital Oncology Clinic
Published 11 February 2021
(UroToday.com) African American men have a 1.6-1.8-fold higher risk of developing prostate cancer, develop prostate cancer at a younger age, and tend to have more aggressive disease at diagnosis. Disparities in prostate cancer outcomes for these men are likely influenced by both socioeconomic and healthcare access issues, as well as genetic factors.  In this study, Dr. Khashab presented genomic data derived from a retrospective analysis of patients treated at a community-focused academic healthcare system in Texas that serves a higher percentage of Hispanic and African American patients with prostate cancer.  ....

United States , Alok Tewari , Harris Health Ben Taub Hospital , Dana Farber Cancer Institute , African American , Tamer Khashab , Ben Taub Hospital , Medical Oncologist , Clinical Oncology Genitourinary Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , அலோக் திவாரி , ஹாரிஸ் ஆரோக்கியம் பென் த்ொஉப் மருத்துவமனை , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , பென் த்ொஉப் மருத்துவமனை , மருத்துவ புற்றுநோயியல் நிபுணர் ,

ASCO GU 2021: Discussant: Enfortumab Vedotin (EV) in Previously Treated Urothelial Cancer


ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion
Published 17 February 2021
(UroToday.com) In this presentation, Arlene O. Siefker-Radtke, MD from the University of Texas MD Anderson Cancer Center provided a discussion on two presentations on Enfortumab Vedotin (EV)  in previously treated urothelial cancer. She first reviewed the results of EV-301 (Abstract 393) which provided level 1 evidence of overall survival benefit with EV compared to single-agent chemotherapy in patients who progressed on platinum chemotherapy and immune checkpoint blockade. The trial schema and relevant overall survival data are re-shown below. EV also demonstrated a progression-free survival benefit and improved overall response rates to 41% from 18% with single-agent chemotherapy. ....

United States , Alok Tewari , Arleneo Siefker Radtke , University Of Texas Md Anderson Cancer Center , Dana Farber Cancer Institute , Medical Oncologist , Clinical Oncology Genitourinary Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , அலோக் திவாரி , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , மருத்துவ புற்றுநோயியல் நிபுணர் ,

ASCO GU 2021: Clinical Conundrums of Genomically Driven Prostate Cancer


Published 12 February 2021
(UroToday.com) The case presented was that of a 54-year-old man with an extensive family history of cancer. His mother died from ovarian cancer, his father had prostate cancer and died of colon cancer, his brother developed kidney and prostate cancer, and his sister had breast and ovarian cancer. The patient had germline testing, which revealed a heterozygous BRCA1 c.1961delA known pathogenic frameshift mutation that leads to a truncated or absent protein. The patient’s medical history was also notable for a pT1 seminoma treated with orchiectomy and radiotherapy (likely unrelated to the BRCA1 alteration) and a recent squamous cell of unknown primary in an inguinal node that was detected during his prostate cancer workup. This was treated with radiotherapy and concurrent 5FU/cisplatin.  ....

Michaelj Morris , Ganesh Palapattu , Maria Isabel Carlo , Alok Tewari , Drug Administration , Dana Farber Cancer Institute , Alejandro Berlin , Federal Drug Administration , Medical Oncologist , Cancers Symposium , மரியா இசபெல் கார்லோ , அலோக் திவாரி , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , அலெஜாண்ட்ரா பெர்லின் , மருத்துவ புற்றுநோயியல் நிபுணர் , புற்றுநோய்கள் சிம்போசியம் ,